Convalescent Plasma Therapy in the management of COVID-19 patients-The newer dimensions

BACKGROUND: COVID 19 infection caused by novel coronavirus with no specific established treatment. Convalescent Plasma Therapy has been authorized as an off-label therapeutic procedure. We assessed the outcome of convalescent plasma (CP) units versus standard treatment on the complete recovery, impr...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahapatra, S., Rattan, R., Mohanty, C.B.K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132190/
https://www.ncbi.nlm.nih.gov/pubmed/33965621
http://dx.doi.org/10.1016/j.tracli.2021.04.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132190/
https://www.ncbi.nlm.nih.gov/pubmed/33965621
http://dx.doi.org/10.1016/j.tracli.2021.04.009

Ejemplares similares